Skip to main content
TipRanks
Go Ultimate75% OFF

Keros Therapeutics (KROS) Drug Pipeline

371 Followers
Drug pipeline
Drug NameConditionStageStatusStudy NameTrial Start DateArticle
Ker-065Duchenne Muscular DystrophyPhase IIRecruitingSafety and Efficacy of KER-065 in Participants With Duchenne Muscular DystrophyJul 09, 2026―
Dose A Ker-012, Dose B Ker-012, Dose C Ker-012Pulmonary Arterial HypertensionPhase IITerminatedA Study to Investigate the Safety and Efficacy of KER-012 in Combination With Background Therapy in Adult Participants With Pulmonary Arterial Hypertension (PAH) (TROPOS Study).Jul 13, 2023

FAQ

What are the FDA phases for drug approval?
The FDA approval process for new drugs is divided into several phases: a. Preclinical testing b. Phase 1 – Safety and dosage c. Phase 2 – Effectiveness and side effects d. Phase 3 – Confirmation of effectiveness, monitoring of adverse reactions, and comparison with existing treatments e. Phase 4 – Post-marketing studies to track long-term safety and effectiveness
What is a clinical trial?
A clinical trial is a carefully designed study in which researchers test a drug, treatment, or medical device in people to evaluate its safety, effectiveness, and potential side effects. These trials are essential for determining whether a new treatment should be approved for widespread use.
What drugs does Keros Therapeutics, Inc. (KROS) have in its pipeline
Keros Therapeutics KROS is currently developing the following drugs: Ker-065, Dose A Ker-012, Dose B Ker-012, Dose C Ker-012. These drug candidates are in various stages of clinical development as the company works toward FDA approval.